|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US20020164788A1
(en)
|
1994-12-02 |
2002-11-07 |
The Wellcome Foundation Limited |
Humanized antibodies to CD38
|
|
US6326144B1
(en)
|
1998-09-18 |
2001-12-04 |
Massachusetts Institute Of Technology |
Biological applications of quantum dots
|
|
CA2345376C
(en)
|
1998-09-24 |
2010-03-16 |
Advanced Research And Technology Institute, Inc. |
Water-soluble luminescent quantum dots and bioconjugates thereof
|
|
US6927203B1
(en)
*
|
1999-08-17 |
2005-08-09 |
Purdue Research Foundation |
Treatment of metastatic disease
|
|
ES2208433T3
(es)
|
1999-12-10 |
2004-06-16 |
Pfizer Products Inc. |
Compuestos de pirrolo(2,3-d)pirimidina como inhibidores de proteina quinasas.
|
|
DK1389617T3
(da)
|
2001-04-27 |
2007-05-07 |
Zenyaku Kogyo Kk |
Heterocyclisk forbindelse og antitumormiddel indeholdende denne som den aktive bestanddel
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
DK1487972T3
(en)
|
2002-02-21 |
2015-10-19 |
Inst Virology |
MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
|
|
IL166718A0
(en)
|
2002-08-14 |
2006-01-15 |
Atugen Ag |
Further use of protein kinase n beta
|
|
EP1452868A2
(en)
|
2003-02-27 |
2004-09-01 |
Pepscan Systems B.V. |
Method for selecting a candidate drug compound
|
|
BRPI0409063A
(pt)
|
2003-04-03 |
2006-03-28 |
Semafore Pharmaceuticals Inc |
pró medicamentos de inibidor de pi-3 cinase
|
|
US7173015B2
(en)
|
2003-07-03 |
2007-02-06 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
|
EP2915820A1
(en)
|
2004-02-06 |
2015-09-09 |
MorphoSys AG |
Anti-CD38 human antibodies and uses therefor
|
|
CA2505655C
(en)
|
2004-04-28 |
2013-07-09 |
Warren Chan |
Stable, water-soluble quantum dot, method of preparation and conjugates thereof
|
|
CA2566609C
(en)
|
2004-05-13 |
2012-06-26 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
WO2006078846A1
(en)
|
2005-01-19 |
2006-07-27 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
PT1844337E
(pt)
|
2005-01-24 |
2014-04-03 |
Pepscan Systems Bv |
Compostos ligantes, compostos imunogénicos e peptidomiméticos
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
AU2006302179C1
(en)
|
2005-10-07 |
2013-06-20 |
Exelixis, Inc. |
N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
|
MY167260A
(en)
|
2005-11-01 |
2018-08-14 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
MX346183B
(es)
|
2005-12-13 |
2017-03-10 |
Incyte Holdings Corp |
Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas heteroarilo-sustituidas como inhibidores de cinasas janus.
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
JP5148597B2
(ja)
|
2006-04-26 |
2013-02-20 |
エフ．ホフマン−ラ ロシュ アーゲー |
医薬化合物
|
|
MY150757A
(en)
|
2006-09-15 |
2014-02-28 |
Siemens Medical Solutions |
Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
|
|
SI2529622T1
(en)
|
2006-09-22 |
2018-06-29 |
Pharmacyclics Llc |
Bruton tyrosine kinase inhibitors
|
|
BRPI0808888B8
(pt)
|
2007-03-12 |
2021-05-25 |
Cytopia Res Pty Ltd |
composto de fenil amino pirimidina para uso no tratamento de uma doença associada à quinase, processo para a preparação do composto, composição farmacêutica, e, implante
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
CN101918844A
(zh)
|
2007-06-18 |
2010-12-15 |
米迪缪尼有限公司 |
表达epha2和erbb2的细胞的协同治疗
|
|
ES2383191T3
(es)
|
2008-02-05 |
2012-06-19 |
Medical Research Council |
Métodos y composiciones
|
|
EA017218B1
(ru)
|
2008-03-11 |
2012-10-30 |
Инсайт Корпорейшн |
Производные азетидина и циклобутана как ингибиторы jak-киназ
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
GB0913775D0
(en)
|
2009-08-06 |
2009-09-16 |
Medical Res Council |
Multispecific peptides
|
|
GB0914110D0
(en)
|
2009-08-12 |
2009-09-16 |
Medical Res Council |
Peptide libraries
|
|
JP2013518807A
(ja)
|
2010-02-04 |
2013-05-23 |
メディカル リサーチ カウンシル |
多重特異性ペプチド
|
|
WO2012057624A1
(en)
|
2010-10-25 |
2012-05-03 |
Pepscan Systems B.V. |
Novel bicyclic peptide mimetics
|
|
SI3299377T1
(sl)
|
2011-10-07 |
2021-07-30 |
Bicyclerd Limited |
Modulacija strukturirane specifičnosti polipeptida
|
|
GB201117428D0
(en)
|
2011-10-07 |
2011-11-23 |
Bicycle Therapeutics Ltd |
Structured polypeptides with sarcosine linkers
|
|
US9790286B2
(en)
*
|
2013-01-02 |
2017-10-17 |
Lucia Irene Gonzalez |
Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis
|
|
JP6548630B2
(ja)
|
2013-03-12 |
2019-07-24 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
特定の細胞型の選択的死滅のための細胞標的化結合領域と志賀毒素ａサブユニット領域とを含む細胞毒性タンパク質
|
|
US20140274759A1
(en)
|
2013-03-15 |
2014-09-18 |
Bicycle Therapeutics Limited |
Modification of polypeptides
|
|
GB201306623D0
(en)
|
2013-04-11 |
2013-05-29 |
Bicycle Therapeutics Ltd |
Modulation of structured polypeptide specificity
|
|
EP2999483B1
(en)
|
2013-05-23 |
2018-10-31 |
Ohio State Innovation Foundation |
Chemical synthesis and screening of bicyclic peptide libraries
|
|
SG11201602889TA
(en)
|
2013-10-28 |
2016-05-30 |
Bicycle Therapeutics Ltd |
Novel polypeptides
|
|
EP3140653B1
(en)
|
2014-05-08 |
2022-05-11 |
Novodiax, Inc. |
Direct immunohistochemistry assay
|
|
PT3149025T
(pt)
|
2014-05-21 |
2019-08-01 |
Entrada Therapeutics Inc |
Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
|
|
PT3215518T
(pt)
*
|
2014-10-29 |
2021-05-25 |
Bicyclerd Ltd |
Ligantes de péptido bicíclicos específicos para mt1-mmp
|
|
WO2016171242A1
(ja)
|
2015-04-24 |
2016-10-27 |
第一三共株式会社 |
Ｅｐｈａ２の検出
|
|
JP2018521960A
(ja)
|
2015-04-28 |
2018-08-09 |
エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） |
酵素で活性化された第ＸＩＩ因子（ＦＸＩＩａ）の新規阻害剤
|
|
EP4219535A1
(en)
*
|
2015-05-18 |
2023-08-02 |
Pieris Pharmaceuticals GmbH |
Anti-cancer fusion polypeptide
|
|
WO2017161069A1
(en)
|
2016-03-16 |
2017-09-21 |
Merrimack Pharmaceuticals, Inc |
Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnosticss
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
MX2018012897A
(es)
|
2016-04-22 |
2019-01-17 |
Alligator Bioscience Ab |
Nuevos polipeptidos biespecificos contra cd137.
|
|
GB201607827D0
(en)
|
2016-05-04 |
2016-06-15 |
Bicycle Therapeutics Ltd |
Bicyclic peptide-toxin conjugates specific for MT1-MMP
|
|
CN109476747A
(zh)
|
2016-05-27 |
2019-03-15 |
艾伯维生物制药股份有限公司 |
结合免疫调节性蛋白和肿瘤抗原的双特异性结合蛋白
|
|
WO2018096365A1
(en)
|
2016-11-27 |
2018-05-31 |
Bicyclerd Limited |
Methods for treating cancer
|
|
MX2019007367A
(es)
|
2016-12-23 |
2020-01-27 |
Bicycletx Ltd |
Ligandos de peptido para enlace a mt1-mmp.
|
|
US11730819B2
(en)
|
2016-12-23 |
2023-08-22 |
Bicycletx Limited |
Peptide derivatives having novel linkage structures
|
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
CA3053803A1
(en)
|
2017-02-24 |
2018-08-30 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
GB201706477D0
(en)
|
2017-04-24 |
2017-06-07 |
Bicycle Therapeutics Ltd |
Modification of polypeptides
|
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
|
EP3661948B1
(en)
|
2017-08-04 |
2022-06-01 |
BicycleTx Limited |
Bicyclic peptide ligands specific for cd137
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US11572370B2
(en)
|
2018-01-08 |
2023-02-07 |
Biohaven Therapeutics Ltd. |
CD16A binding agents and uses thereof
|
|
WO2019162682A1
(en)
*
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
US11453703B2
(en)
|
2018-04-04 |
2022-09-27 |
Bicycletx Limited |
Heterotandem bicyclic peptide complexes
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
GB201810325D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicycletx Ltd |
Peptide ligands for binding to PSMA
|
|
CN112955459A
(zh)
|
2018-10-23 |
2021-06-11 |
拜斯科技术开发有限公司 |
双环肽配体和其用途
|
|
KR20210123295A
(ko)
|
2018-12-13 |
2021-10-13 |
바이사이클티엑스 리미티드 |
Mt1-mmp에 특이적인 이환식 펩티드 리간드
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3897851A2
(en)
|
2018-12-17 |
2021-10-27 |
Revitope Limited |
Twin immune cell engager
|
|
WO2020128526A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicycletx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
CN113260420A
(zh)
|
2018-12-21 |
2021-08-13 |
拜斯科阿迪有限公司 |
Pd-l1特异性的双环肽配体
|
|
EP3946462A1
(en)
|
2019-04-02 |
2022-02-09 |
BicycleTX Limited |
Bicycle toxin conjugates and uses thereof
|
|
KR20220007098A
(ko)
|
2019-05-09 |
2022-01-18 |
바이사이클티엑스 리미티드 |
Ox40에 특이적인 이환식 펩티드 리간드
|
|
TW202118770A
(zh)
|
2019-07-30 |
2021-05-16 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
EP4013501A1
(en)
|
2019-08-13 |
2022-06-22 |
BicycleTX Limited |
Modified multimeric bicyclic peptide ligands
|
|
WO2021064428A1
(en)
|
2019-10-03 |
2021-04-08 |
Bicycletx Limited |
Heterotandem bicyclic peptide complexes
|
|
KR20220131898A
(ko)
|
2019-11-27 |
2022-09-29 |
바이사이클티엑스 리미티드 |
ＥｐｈＡ２에 특이적인 바이사이클릭 펩티드 리간드 및 이의 용도
|
|
AU2021289095A1
(en)
|
2020-06-12 |
2023-01-05 |
Bicycletx Limited |
Treatment of diseases characterized by overexpression of Erythropoietin-producing hepatocellular receptor A2 (EphA2)
|
|
KR20230074721A
(ko)
|
2020-08-17 |
2023-05-31 |
바이사이클티엑스 리미티드 |
Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
|
|
AU2022206577A1
(en)
|
2021-01-08 |
2023-08-24 |
Bicycletx Limited |
Heterotandem bicyclic peptide complexes
|
|
US20240325554A1
(en)
|
2021-01-11 |
2024-10-03 |
Bicycle TX Limited |
Methods for treating cancer
|